Taysha Gene Therapies, Inc. (TSHA) fair value analysis
Nasdaq · Updated 2026-10-19
TSHA price how computed
Valuation status
No fair-value estimate yetTSHA has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TSHA yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.62
- Sector
- Healthcare
- 12-month range
- $3.51–$6.98
- Market cap
- $1.18B
- From 52-week high
- -48.1%
- Shares outstanding
- 326M
- Rank in Healthcare by quality score
- #273 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing gene therapy treatments for rare neurological diseases. The company is headquartered in Dallas, Texas and operates in the healthcare sector as a Nasdaq-listed entity.
TSHA currently ranks #273 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.18B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $5.48M
- Net margin
- -2728.0%
- EPS (TTM)
- $-0.40
- Debt / equity
- 0.14
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 326M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 25 · oversold
- 50-day average
- $5.26
- 200-day average
- $5.38
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 3 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-18.2%)
2026-03 ▼ miss (-10.0%)
2025-12 ▲ beat (+23.4%)
2025-09 ▬ met (0.0%)
2025-06 ▼ miss (-14.3%)
2025-03 ▬ met (0.0%)
2024-12 ▲ beat (+12.5%)
2024-09 ▲ beat (+22.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 0 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $13
- Target vs last price
- +259.1%
What our data shows for TSHA
- Shares are trading in the lower third of their 12-month price range of $3.51–$6.98.
- The 14-day relative strength index sits at an oversold 25.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TSHA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the TSHA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TSHA's relative strength index moved into oversold territory this week, shifting from a neutral zone classification. The stock remains in the Healthcare sector with a valuation verdict that is currently awaiting full analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for TSHA in the Healthcare sector showed movement this week as the RSI zone shifted from oversold to neutral. The stock's current valuation verdict remains awaiting full valuation. No other indicator changes were reported for the week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TSHA stock undervalued?
TickrTrends has no fair-value estimate for TSHA yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TSHA's TickrTrends verdict?
TSHA is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TSHA compare to other Healthcare stocks?
TSHA ranks #273 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TSHA overbought or oversold?
TSHA's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does TSHA report earnings next?
TSHA's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does TSHA usually beat earnings estimates?
Over its last 8 reported quarters TSHA beat the consensus estimate 3 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TSHA?
Of 13 analysts covering TSHA, 13 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $13 (+259.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.